Trump administration set to announce drug pricing deals

• The new deals build on agreements with major pharmaceutical companies starting last year, where drugmakers agreed to lower prices for federal health programs and sell medicines directly through a Trump-branded website in exchange for regulatory relief
• Smaller and mid-sized drugmakers have been slow to participate, with only Japan's Astellas confirmed as applying for the Medicaid pricing program by earlier this year, as executives see limited financial incentive
• The administration claims its broader drug pricing push could save $150 billion in federal and state spending over the next decade, though this figure is speculative and actual savings for government or patients remain unclear

Summary: Trump Administration Announces New Drug Pricing Deals

The Trump administration is set to announce additional drug pricing agreements on August 31, with participating companies expected to include Bayer, Takeda, CSL, and several mid-size biotechnology firms, according to the Financial Times. The announcement is scheduled for 3 p.m. ET at a White House healthcare affordability event.

Key Issue: U.S. patients currently pay nearly three times more for prescription drugs compared to other developed nations, prompting the administration's push for "most-favored-nation" pricing.

Program Details: These new deals build on previous agreements with major pharmaceutical companies including Pfizer, Eli Lilly, and Amgen established last year. Participating drugmakers agree to:

• Offer lower prices comparable to other developed countries
• Cut prices for federal health programs
• Sell medicines directly to patients through a Trump-branded website
• Receive regulatory relief in return

Challenges: Smaller and mid-sized drugmakers have been slow to participate. Reuters previously reported that only Japan's Astellas confirmed applying for the Medicaid pricing program, with companies like Ionis Pharmaceuticals citing limited financial incentives. Medicaid already receives steep discounts under existing law, and most beneficiaries pay minimal out-of-pocket costs.

Financial Impact: The administration claims its broader drug pricing initiatives could save billions in federal and state spending over the next decade, though this figure remains speculative. Actual savings for the government and patients from these deals remain unclear.

Political Context: The announcement comes as part of the administration's broader healthcare affordability push ahead of midterm elections that will determine Congressional control.